BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24697863)

  • 1. Molecular dynamics simulations reveal a novel mechanism for ATP inhibition of insulin degrading enzyme.
    da Cruz CH; Seabra G
    J Chem Inf Model; 2014 May; 54(5):1380-90. PubMed ID: 24697863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QM/MM simulations of amyloid-β 42 degradation by IDE in the presence and absence of ATP.
    da Cruz CH; Seabra GM
    J Chem Inf Model; 2015 Jan; 55(1):72-83. PubMed ID: 25539133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of interactions of Alzheimer amyloid beta peptides (Abeta40 and Abeta42) with insulin degrading enzyme: a molecular dynamics study.
    Bora RP; Prabhakar R
    Biochemistry; 2010 May; 49(18):3947-56. PubMed ID: 20380468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides.
    Kurochkin IV; Guarnera E; Wong JH; Eisenhaber F; Berezovsky IN
    Biochemistry; 2017 Jan; 56(1):228-239. PubMed ID: 27982586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation of Alzheimer's Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme.
    Sahoo BR; Panda PK; Liang W; Tang WJ; Ahuja R; Ramamoorthy A
    J Mol Biol; 2021 Jun; 433(13):166993. PubMed ID: 33865867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity.
    Ciaccio C; Tundo GR; Grasso G; Spoto G; Marasco D; Ruvo M; Gioia M; Rizzarelli E; Coletta M
    J Mol Biol; 2009 Feb; 385(5):1556-67. PubMed ID: 19073193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
    Çakir B; Dağliyan O; Dağyildiz E; Bariş İ; Kavakli IH; Kizilel S; Türkay M
    PLoS One; 2012; 7(2):e31787. PubMed ID: 22355395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple allosteric sites are involved in the modulation of insulin-degrading-enzyme activity by somatostatin.
    Tundo GR; Di Muzio E; Ciaccio C; Sbardella D; Di Pierro D; Polticelli F; Coletta M; Marini S
    FEBS J; 2016 Oct; 283(20):3755-3770. PubMed ID: 27579517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.
    Im H; Manolopoulou M; Malito E; Shen Y; Zhao J; Neant-Fery M; Sun CY; Meredith SC; Sisodia SS; Leissring MA; Tang WJ
    J Biol Chem; 2007 Aug; 282(35):25453-63. PubMed ID: 17613531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.
    Shen Y; Joachimiak A; Rosner MR; Tang WJ
    Nature; 2006 Oct; 443(7113):870-4. PubMed ID: 17051221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.
    Guo Q; Manolopoulou M; Bian Y; Schilling AB; Tang WJ
    J Mol Biol; 2010 Jan; 395(2):430-43. PubMed ID: 19896952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolytic fragments of insulysin (IDE) retain substrate binding but lose allosteric regulation.
    Song ES; Cady C; Fried MG; Hersh LB
    Biochemistry; 2006 Dec; 45(50):15085-91. PubMed ID: 17154546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme.
    Malito E; Ralat LA; Manolopoulou M; Tsay JL; Wadlington NL; Tang WJ
    Biochemistry; 2008 Dec; 47(48):12822-34. PubMed ID: 18986166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Longest Amyloid-β Precursor Protein Intracellular Domain Produced with Aβ42 Forms β-Sheet-Containing Monomers That Self-Assemble and Are Proteolyzed by Insulin-Degrading Enzyme.
    Krasinski CA; Zheng Q; Ivancic VA; Spratt DE; Lazo ND
    ACS Chem Neurosci; 2018 Dec; 9(12):2892-2897. PubMed ID: 30067897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation.
    Cordes CM; Bennett RG; Siford GL; Hamel FG
    Biochem Pharmacol; 2009 Mar; 77(6):1064-73. PubMed ID: 19154729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copper(I) and copper(II) inhibit Aβ peptides proteolysis by insulin-degrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease.
    Grasso G; Pietropaolo A; Spoto G; Pappalardo G; Tundo GR; Ciaccio C; Coletta M; Rizzarelli E
    Chemistry; 2011 Feb; 17(9):2752-62. PubMed ID: 21274957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Determinants of Substrate Specificity in Human Insulin-Degrading Enzyme.
    Stefanidis L; Fusco ND; Cooper SE; Smith-Carpenter JE; Alper BJ
    Biochemistry; 2018 Aug; 57(32):4903-4914. PubMed ID: 30004674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of insulin-degrading enzyme in insulin- and atrial natriuretic peptide-sensitive internalization of amyloid-β peptide in mouse brain capillary endothelial cells.
    Ito S; Ohtsuki S; Murata S; Katsukura Y; Suzuki H; Funaki M; Tachikawa M; Terasaki T
    J Alzheimers Dis; 2014; 38(1):185-200. PubMed ID: 23948938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.
    Farris W; Leissring MA; Hemming ML; Chang AY; Selkoe DJ
    Biochemistry; 2005 May; 44(17):6513-25. PubMed ID: 15850385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anion activation site of insulin-degrading enzyme.
    Noinaj N; Song ES; Bhasin S; Alper BJ; Schmidt WK; Hersh LB; Rodgers DW
    J Biol Chem; 2012 Jan; 287(1):48-57. PubMed ID: 22049080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.